Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Comment by bionicjoeon Jan 20, 2019 9:53am
82 Views
Post# 29256731

RE:RE:RE:back to $ 7 again next week

RE:RE:RE:back to $ 7 again next week
orphanblack wrote:

maybe not 7 but back to 7's for sure next week, nothing to do with charts, everything to do with revenue, expenses and dilution, acb is so vulnerable that good news from other lp's will cause money to flow from here, whistler was last chance to get out at a good price


I take it that you don't believe Cam Battley's explanation of their most recent financial instrument will carry any positive weight with the market next week? One would think that once they grow their production to 500,000 kg per year resulting in potentially over a billion dollars in revenue each year, having to pay $15 million in annual interest rates would be considered pocket change.

Whistler was a good buy. It added a top organic brand to their inventory to round out their catalog of selections to the cannabis shopper. If you want quality you're going to have to pay for it. There is a segment of the consumer market who doesn't mind paying for the best.

Not all LPs are cut out of the same cloth. Aurora has elected to build shareholder value first before partnering with a major multinational whereas Canopy and Cronus chose to give away more of their independence earlier in their development cycle  Frustrating no doubt for ACB longs but IMO the frustration will only be temporary. A more productive money generating Aurora will undoubtedly attract bigger players to the bargaining table later on which in turn will result in a more lucrative deal for those shareholders who choose to buy into the company philosophy. That's what Cam was trying to get across in the Midas interview. Wait and the reward will be greater.

Don't judge Aurora by January news but by July and then December. Mid year to see if we are going in the right direction and the end of year to confirm we are. IMO, the market won't recognize how much ACB has bulked up by the end of 2019.

Bullboard Posts